Home / Health / Affordable Drug Offers Hope for Diabetic Kidney Disease Patients
Affordable Drug Offers Hope for Diabetic Kidney Disease Patients
13 Nov
Summary
- Chronic kidney disease now 5th leading cause of death worldwide
- Diabetes is the leading cause of chronic kidney disease in India
- Levocetirizine shows potential to reduce albuminuria and inflammation
Chronic kidney disease (CKD) has emerged as a significant global health challenge, now ranking as the fifth leading cause of death worldwide. Unlike heart disease and cancer, the prevalence of CKD continues to rise steadily, with symptoms often appearing only in the advanced stages, earning it the label of a "silent killer."
In India, a 1999 study from SGPGI, Lucknow was among the first to highlight that diabetes, once considered a disease of affluence, has become the most common cause of end-stage renal disease in the country. Subsequent data has confirmed this trend, with diabetes now the leading driver of CKD in India.
While new therapeutic options like Flozins, Finerenone, and Semaglutide have shown remarkable efficacy in reducing the progression of diabetic kidney disease, these drugs remain expensive and cannot entirely halt disease progression. Against this backdrop, the recent trial with the inexpensive and well-tolerated drug Levocetirizine represents a significant development.
